Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

Immunotherapy (Investigational Checkpoint) (11)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type
Bavituximab	TIM-3 / LAG-3 / TIGIT Inhibitor	Both (Solid & Hematologic)
Molecule Bavituximab Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Cobolimab	TIM-3 / LAG-3 / TIGIT Inhibitor	Both (Solid & Hematologic)
Molecule Cobolimab Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Sabatolimab	TIM-3 / LAG-3 / TIGIT Inhibitor	Both (Solid & Hematologic)
Molecule Sabatolimab Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Eftilagimod Alfa	TIM-3 / LAG-3 / TIGIT Inhibitor	Both (Solid & Hematologic)
Molecule Eftilagimod Alfa Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Favezelimab	TIM-3 / LAG-3 / TIGIT Inhibitor	Both (Solid & Hematologic)
Molecule Favezelimab Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Domvanalimab	TIM-3 / LAG-3 / TIGIT Inhibitor	Both (Solid & Hematologic)
Molecule Domvanalimab Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Etigilimab	TIM-3 / LAG-3 / TIGIT Inhibitor	Both (Solid & Hematologic)
Molecule Etigilimab Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Belrestotug	TIM-3 / LAG-3 / TIGIT Inhibitor	Both (Solid & Hematologic)
Molecule Belrestotug Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Ociperlimab	TIM-3 / LAG-3 / TIGIT Inhibitor	Both (Solid & Hematologic)
Molecule Ociperlimab Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Rilvegostomig	TIM-3 / LAG-3 / TIGIT Inhibitor	Both (Solid & Hematologic)
Molecule Rilvegostomig Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
BMS-986258	TIM-3 / LAG-3 / TIGIT Inhibitor	Both (Solid & Hematologic)
Molecule BMS-986258 Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor

Bavituximab Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Cobolimab Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Sabatolimab Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Eftilagimod Alfa Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Favezelimab Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Domvanalimab Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Etigilimab Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Belrestotug Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Ociperlimab Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
Rilvegostomig Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
BMS-986258 Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor

Product Range

Company

Global Network

Products

Bavituximab

Cobolimab

Sabatolimab

Eftilagimod Alfa

Favezelimab

Domvanalimab

Etigilimab

Belrestotug

Ociperlimab

Rilvegostomig

BMS-986258